Intake of Energy Drinks Before and During Pregnancy and Adverse Pregnancy Outcomes

被引:5
|
作者
Ding, Ming [1 ,2 ]
Markon, Andre O. [3 ]
Jones-Dominic, Olivia E. [3 ]
Purdue-Smithe, Alexandra C. [4 ,5 ]
Rich-Edwards, Janet W. [4 ,5 ]
Wolpert, Beverly J. [3 ]
Chavarro, Jorge E. [2 ,5 ,6 ,7 ,8 ]
机构
[1] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA
[2] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[3] US FDA, Ctr Food Safety & Appl Nutr, Off Analyt & Outreach, College Pk, MD USA
[4] Brigham & Womens Hosp, Div Womens Hlth, Boston, MA USA
[5] Harvard Med Sch, Boston, MA USA
[6] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA USA
[7] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[8] Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA
关键词
HYPERTENSIVE DISORDERS; DIETARY QUESTIONNAIRE; HEALTH; CONSUMPTION; VALIDITY; REPRODUCIBILITY; VALIDATION; DISEASE; IMPACT; RISK;
D O I
10.1001/jamanetworkopen.2023.44023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance: Consumption of energy drinks has increased drastically in recent years, particularly among young people. It is unknown whether intake of energy drinks is associated with health during pregnancy.Objective: To examine associations of energy drink intake before and during pregnancy with risk of adverse pregnancy outcomes (APOs).Design, setting, and participants: This prospective cohort study included data from women enrolled in the Nurses' Health Study 3 (NHS3) between June 1, 2010, and September 27, 2021, and the Growing Up Today Study (GUTS) who reported 1 or more singleton pregnancy from January 1, 2011, to June 1, 2019. Data were analyzed from October 1, 2021, to September 28, 2023.Exposure: Intake of energy drinks, assessed by food frequency questionnaire.Main outcomes and measures: The main outcomes were self-reported APOs, including pregnancy loss, gestational diabetes, gestational hypertension, preeclampsia, or preterm birth, and a composite APO, defined as development of any of the APOs. Risk of APOs was compared between consumers and nonconsumers of energy drinks.Results: This study included 7304 pregnancies in 4736 participants with information on prepregnancy energy drink intake and 4559 pregnancies in 4559 participants with information on energy drink intake during pregnancy. There were 1691 GUTS participants (mean [SD] age, 25.7 [2.9] years) and 3045 NHS3 participants (mean [SD] age, 30.2 [4.1] years). At baseline, 230 GUTS participants (14%) and 283 NHS3 participants (9%) reported any intake of energy drinks. While no associations were found for pregnancy loss (odds ratio [OR], 0.89; 95% CI, 0.71-1.11), preterm birth (OR, 1.07; 95% CI, 0.71-1.61), gestational diabetes (OR, 0.89; 95% CI, 0.58-1.35), preeclampsia (OR, 0.73; 95% CI, 0.41-1.30), or the composite APO (OR, 1.05; 95% CI, 0.87-1.26), prepregnancy energy drink use was associated with a higher risk of gestational hypertension (OR, 1.60; 95% CI, 1.12-2.29). A significant interaction was found between age and energy drink intake in relation to hypertensive disorders (P = .02 for interaction for gestational hypertension; P = .04 for interaction for any hypertensive disorders), with stronger associations for participants above the median age. No associations of energy drink intake during pregnancy with any of the APOs were found in NHS3 (eg, any APO: OR, 0.86; 95% CI, 0.41-1.79).Conclusions and relevance: In this study, energy drink intake before pregnancy was associated with an elevated risk of gestational hypertension. Given the low prevalence of energy drink intake and low consumption levels among users, the results should be interpreted cautiously.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Adverse outcomes of renovascular hypertension during pregnancy
    Thorsteinsdottir, Bjorg
    Kane, Garvan C.
    Hogan, Michael J.
    Watson, William J.
    Grande, Joseph P.
    Garovic, Vesna D.
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2006, 2 (11): : 651 - 656
  • [22] Ceramides during Pregnancy and Obstetrical Adverse Outcomes
    Lantzanaki, Maria
    Vavilis, Theofanis
    Harizopoulou, Vikentia C.
    Bili, Helen
    Goulis, Dimitrios G.
    Vavilis, Dimitrios
    METABOLITES, 2023, 13 (11)
  • [24] Adverse outcomes of renovascular hypertension during pregnancy
    Bjorg Thorsteinsdottir
    Garvan C Kane
    Michael J Hogan
    William J Watson
    Joseph P Grande
    Vesna D Garovic
    Nature Clinical Practice Nephrology, 2006, 2 : 651 - 656
  • [25] Trends in smoking and overweight during pregnancy: Prevalence, risks of pregnancy complications, and adverse pregnancy outcomes
    Cnattingius, S
    Lambe, M
    SEMINARS IN PERINATOLOGY, 2002, 26 (04) : 286 - 295
  • [26] Vaginal colonization by microbes during early pregnancy and their association with adverse pregnancy outcomes
    Tellapragada, C.
    Eshwara, V. Kalwaje
    Bhat, P.
    Kamath, A.
    Mukhopadhyay, C.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 342 - 342
  • [27] Syphilis infection during pregnancy: an essential contributor to adverse pregnancy and neonatal outcomes
    Bornstein, Eran
    Eliner, Yael
    Gulersen, Moti
    Grunebaum, Amos
    Lenchner, Erez
    Bar-El, Liron
    Chervenak, Frank
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : S388 - S389
  • [28] Assessing adverse pregnancy outcomes and fetal malformations in cancer diagnosed during pregnancy
    Ouh, Yung-Taek
    Jeon, Hyunyu
    Eun, Seoyun
    Moon, Hye Yeon
    Min, Kyung Jin
    Lee, Jae-Kwan
    Lee, Nak Woo
    Cho, Geum Joon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S402 - S402
  • [29] Woman's perceived stress during pregnancy; stressors and pregnancy adverse outcomes
    Kashanian, Maryam
    Faghankhani, Masoomeh
    YousefzadehRoshan, Masoomeh
    EhsaniPour, Mohammad
    Sheikhansari, Narges
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2021, 34 (02): : 207 - 215
  • [30] Increased Risk of Adverse Pregnancy Outcomes in Women Receiving Zolpidem During Pregnancy
    Wang, L-H
    Lin, H-C
    Lin, C-C
    Chen, Y-H
    Lin, H-C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (03) : 369 - 374